Phase 0-1 Clinical Trials

DTB和DCTD之间的合作开发了几种新的药效学检测方法，包括肿瘤组织活检中伽马H2AX （DNA双链断裂检测器）的超灵敏免疫荧光检测，拓扑异构酶I和聚adp核糖聚合酶（PARP）的elisa，以及其他DNA损伤标记物（pNBS1）， MEK， ERK和AKT的所有同工型，dnmt，以及一系列免疫pd标记物的检测。这些检测对于在NIH临床中心激活的新型非喜树碱拓扑异构酶I抑制剂、DNMT1抑制剂和免疫治疗组合的首次人体临床试验至关重要。此外，与儿科肿瘤科的合作促进了用于罕见肿瘤的新药的开发。围绕我们在系统药理学中使用NCI 60，已经开展了更多的合作。

The collaboration between the DTB and DCTD has been responsible for the development of several new pharmacodynamic assays, including an ultrasensitive immunofluorescence assay for gamma H2AX (DNA double strand break detector) in tumor tissue biopsies, and ELISAs for topoisomerase I and poly ADP-ribose polymerase (PARP), as well as assays for other DNA damage markers (pNBS1), all of the isoforms of MEK, ERK, and AKT, DNMTs, as well as a series of immuno-PD markers. These assays have been essential for first in human clinical trials of novel non-camptothecin topoismerase I inhibitors, DNMT1 inibitors, and immunotherapy combinations that have been activated in the NIH Clinical Center. In addition, collaborations with the Pediatric Oncology Branch have facilitated the development of new agents used for rare tumors. Additional collaborations have developed around our use of the NCI 60 for systems pharmacology.